Statement of Principles concerning myeloma (Reasonable Hypothesis) (No. 95 of 2021)

This instrument sets out the Repatriation Medical Authority's Statement of Principles (SoP) that establishes what factual circumstances, exposures and medical conditions will satisfy the statutory test of a "reasonable hypothesis" connecting myeloma, or death from myeloma, with a person’s relevant service under the Veterans' Entitlements Act 1986 (VEA) or the Military Rehabilitation and Compensation Act 2004 (MRCA). The instrument was made under subsection 196B(2) of the VEA (s 3) and expressly applies to claims to which section 120A of the VEA or section 338 of the MRCA applies (s 5). It therefore operates as a technical evidentiary and causal gate in the administration of entitlements rather than as primary substantive entitlement law.

Mechanically, the instrument performs these functions:

• Defines the injury/disease to which the SoP applies, namely myeloma and death from myeloma, by reference to a biomedical definition in s 7(2) and by noting the ICD‑10‑AM code C90 while making clear that the statutory meaning is the textual definition rather than the code alone (s 7(2)-(4)).
• Identifies a closed list of factors which, if at least one is established and linked to a claimant’s relevant service, will raise the reasonable hypothesis that the myeloma is connected to service (s 9). The required factors are expressed as quantitative thresholds, timing rules and categorical conditions (for example, cumulative radiation dose, benzene exposure metrics, Vietnam service of defined duration, HIV infection, specified organ transplants, BMI thresholds, certain autoimmune diseases, and an inability to obtain appropriate clinical management).
• Requires the nexus between any listed factor and the person’s relevant service as a matter of law (s 10(1)). It limits the application of the “inability to obtain appropriate clinical management” factor to contributions or aggravation where myeloma pre‑existed or was contracted before or during service (s 10(2)).
• Incorporates by reference other SoPs where a listed factor itself refers to a disease already covered by a separate SoP (s 11).
• Supplies detailed definitions in Schedule 1, which operationalise the thresholds and terms used in the factors, including technical cross‑references to external instruments such as the ARPANSA Guide for dose calculation and the ICD‑10‑AM edition specified (Schedule 1, various definitions).

The instrument does not itself create an entitlement, award benefits, impose criminal penalties, or set administrative processes for deciding claims. Rather, it provides the medical/causal criteria that the decision maker under the VEA or MRCA will use to decide whether a reasonable hypothesis exists. The RMA records an evidentiary judgment that there is sound medical‑scientific evidence supporting a relationship between the disease and service (s 8), but the instrument’s effect is procedural: it shapes how claim evidence is assessed by the administration applying the statutory claim provisions cited in s 5.

The core legal and technical concepts are: myeloma as defined in the instrument; the reasonable hypothesis standard; the list of qualifying factors; temporal and quantitative thresholds; and the requirement that any qualifying factor be related to relevant service.

Myeloma and death from myeloma

• The instrument defines myeloma in substantive biomedical terms: a malignant disease of plasma cells in which a single line of plasma cells accumulates and produces a monoclonal immunoglobulin (s 7(2)(a)). It specifies that extramedullary plasmacytoma, multiple myeloma, plasma cell leukaemia and solitary plasmacytoma of bone are included (s 7(2)(b)(i)-(iv)). While the ICD‑10‑AM code C90 is noted (s 7(3)), the statutory meaning is the textual definition given in s 7(2).

Reasonable hypothesis

• The SoP identifies factors that must exist "before it can be said that a reasonable hypothesis has been raised connecting myeloma or death from myeloma with the circumstances of a person's relevant service" (s 9). The instrument therefore operationalises the legal standard used by decision makers to infer causal connection from service to disease for the purpose of entitlement processes under the VEA and MRCA.

Qualifying factors and thresholds

• Section 9 contains eleven numbered factors. Several are quantitative and time‑bounded. Examples:
  • Ionising radiation: a cumulative equivalent dose to bone marrow of at least 0.1 sievert, with onset at least five years later (s 9(1) and Note re cumulative equivalent dose in Schedule 1).
  • Chemical contamination with TCDD (dioxin): cumulative contact of at least 1,000 hours within a consecutive 10‑year period and first exposure at least 5 years before onset (s 9(2)).
  • Vietnam service: being on land in Vietnam or at sea in Vietnamese waters, or consuming potable water produced by evaporative distillation of estuarine Vietnamese waters, for a cumulative total of at least 30 days, and at least 5 years before clinical onset (s 9(3)).
  • Benzene: either at least 2,500 cumulative hours within a continuous 5‑year period and first exposure at least 5 years before onset (s 9(6)); or cumulative exposure greater than 10 ppm‑years and first exposure at least 5 years before onset (s 9(7)). Schedule 1 defines the exposure metrics including 8‑hour time‑weighted averages and what constitutes exposure by contact, ingestion or inhalation.
  • Obesity or overweight: BMI of 25 or greater for a continuous period of at least 5 years before onset (s 9(8) and Schedule 1 definition).

The instrument affects claimants, decision makers and persons involved in compiling evidentiary material for veterans and members of the Forces, and it creates demand for particular technical assessments and records.

Primary affected persons

• Veterans, members of Peacekeeping Forces and members of the Forces whose service qualifies as "relevant service" under the Schedule 1 definition are directly affected when they lodge claims for myeloma or death from myeloma under VEA or MRCA provisions covered by this SoP (s 5 and Schedule 1 relevant service definition). The list of "relevant service" categories is broad, including operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike and non‑warlike service under the MRCA (Schedule 1).

Claim administrators and medical assessors

• Administrative decision makers responsible for determining claims under the VEA and MRCA will use this SoP as the medical‑causal yardstick for raising or rejecting the reasonable hypothesis that myeloma is connected to service. Although the SoP itself is made by the Repatriation Medical Authority (s 3 and s 8), the practical decision on entitlement will be taken by the statutory decision maker exercising powers under the VEA or MRCA (see s 5).

Health‑care providers and occupational hygienists

• The instrument requires technical quantification of exposures and conditions. For example, establishing cumulative equivalent ionising radiation dose to bone marrow requires applying the ARPANSA Guide methodology specified in Schedule 1. Establishing benzene exposures requires reconstructing 8‑hour time‑weighted averages and calculating ppm‑years or cumulative hours. Medical records need to show diagnosis timing and comorbidities like autoimmune disease or HIV infection. Clinicians, occupational hygienists and radiation dose reconstruction specialists therefore supply the evidence that claimants must produce.

Third‑party record holders

• Employers, service record custodians, unit medical records, ship logs, industrial hygiene records, and supply/maintenance records (for chemical exposure events and potable water production methods) are likely sources of evidence. The SoP’s Vietnam water provision refers specifically to consumable water produced by evaporative distillation of estuarine Vietnamese waters (s 9(3)(c) and Schedule 1 potable/estuarine definitions). That creates a need to identify shipboard water production methods in historic records.

The instrument frames duties and evidentiary rights only in the context of the reasonable hypothesis test for the connection between myeloma and service. It does not create general statutory duties or civil rights outside the claims process.

Duty to relate factors to relevant service

• Section 10(1) imposes a legal requirement: any factor present under s 9 must be related to the person’s relevant service. This is not an evidentiary nicety; it is a substantive legal requirement to be satisfied as part of raising the reasonable hypothesis. The duty to show that the exposure or condition was service‑related will fall on the claimant insofar as the claims process requires proof of service nexus.

Time and threshold compliance duties

• Several factors include explicit timing and threshold requirements that operate as conditions precedent to the reasonable hypothesis being raised. Examples that will commonly appear as duties on claim preparation:
  • Provide evidence that the first relevant exposure occurred at least five years before clinical onset, where specified (s 9(1), (2)(b), (3), (6)-(7)).
  • For benzene exposures, provide quantitative evidence of either cumulative hours or ppm‑years as defined in Schedule 1; for inhalation exposures, show ambient 8‑hour time‑weighted average benzene concentrations exceeding 5 ppm (Schedule 1 benzene definitions).
  • For radiation exposures, supply dose estimates computed in accordance with the ARPANSA Guide method noted in Schedule 1.

Duty to apply definitions and external methods

• The instrument incorporates definitions and external methodologies by reference. Claimants and assessors must apply the specified ARPANSA Guide for dose reconstruction and the named edition of ICD‑10‑AM (s 7(4) and Schedule 1). Compliance therefore requires use of those texts in their stated versions.

Rights triggered by a raised reasonable hypothesis

• While the instrument does not itself set out the remedies or entitlements, the statutory purpose of an SoP is to guide whether a reasonable hypothesis connects disease and service, which activates procedural and substantive processes under the VEA or MRCA. If a claimant establishes a factor listed in s 9 and it is related to relevant service under s 10(1), the SoP is intended to ground a finding that the reasonable hypothesis has been raised. That finding is consequential for claim resolution under the primary Acts (s 5) but the instrument does not spell out the administrative steps or entitlement outcomes; those are governed by VEA/MRCA provisions referenced in s 5.

This instrument itself contains no penalties, criminal offences or administrative penalty provisions. Its function is determinate and technical: to set the medical‑causal criteria that will be used when decision makers evaluate whether a reasonable hypothesis connects myeloma or death from myeloma to relevant service. The SoP therefore influences enforcement and outcomes indirectly by informing decisions under the VEA and MRCA, but it does not itself prescribe enforcement mechanisms.

Mechanism of effect

• The instrument’s enforceable effects arise because it is made under s 196B(2) of the VEA (s 3) and applies to claims under s 120A VEA or s 338 MRCA (s 5). Those statutory provisions govern claims and entitlements. The administrative decision maker applying those provisions will treat the presence of a qualifying factor listed in this SoP, related to relevant service, as raising the reasonable hypothesis. The practical enforcement of that conclusion occurs through the decision processes and appeal routes set out in the VEA and MRCA, not via this instrument.

No sanctioning powers

• There are no sanctioning powers specified for non‑compliance with definitions or reporting obligations. The instrument does not create duties on third parties that are enforced by penalties. For example, there is no obligation on employers to preserve records under penalty; rather, the absence of records may affect a claimant’s ability to establish a listed factor and therefore to raise the reasonable hypothesis.

Evidentiary consequences

• The principal "enforcement" effect is evidentiary: meeting the thresholds and nexus requirements described in ss 7-11 produces an evidentiary presumption or triggers an administrative inference used in adjudication under the VEA or MRCA. That changes the burden of proof dynamics in claim resolution, but any specific remedy, payment or sanction flowing from a successful claim is governed by the primary Acts.

Administrative discretion and potential follow‑up

• While the SoP is precise about factors and thresholds, decision makers retain the procedural discretion to accept or reject evidence and to commission further technical assessments such as dose reconstruction. The instrument references the ARPANSA Guide and ICD‑10‑AM editions, so enforcement of the SoP in practice will involve technical verification and possible further expert evidence. The instrument does not limit the administrative discretion in determining whether the qualifying factor is sufficiently proven; it defines what must be proven.

The instrument expressly interacts with the VEA and MRCA, with external technical standards, and with other Statements of Principles determined under s 196B(2) of the VEA.

Interaction with primary statutes

• Authority: The SoP is made under subsection 196B(2) of the VEA (s 3). Its applicability to claim adjudication is explicit: it applies to claims to which s 120A of the VEA or s 338 of the MRCA applies (s 5). Consequently, it functions as a subordinate instrument that feeds into the decision framework and evidentiary standards used under the primary Acts.

Cross‑SoP application

• Section 11 provides a mechanism for integrated application where a factor in this SoP refers to an injury or disease already the subject of another SoP. In such cases, the instrument directs that the factors in that other SoP apply "in accordance with the terms of that Statement of Principles as in force from time to time." This creates a chain of reference between SoPs and requires decision makers to apply multiple instruments when exposures or diseases overlap.

References to external technical instruments

• The instrument specifies external technical sources that must be used for particular determinations:
  • ICD‑10‑AM Tenth Edition, effective 1 July 2017, for code references (s 7(4)). The instrument clarifies that even where myeloma attracts code C90, the statutory meaning is the textual definition (s 7(3)-(4)).
  • Guide to calculation of "cumulative equivalent dose" as in force on 2 August 2017, published by the Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), for radiation dose calculations (Schedule 1 cumulative equivalent dose definition).
• These incorporations mean that the SoP’s application depends on those external texts as of specified versions and dates. Any later editions or methodological changes will be relevant only to the extent the SoP is amended or the specified editions are updated in subsequent SoPs.

Interaction with VEA Schedule 2 (Vietnam service)

• The Schedule 1 definition of "being on land in Vietnam or at sea in Vietnamese waters" and "estuarine Vietnamese waters" ties the geographic and temporal scope to Items 3A, 3B, 4 and 8 of Schedule 2 of the VEA (Schedule 1 definitions). The 2024 amendment explicitly revises that dictionary entry (see endnote 4). Therefore, to determine whether the Vietnam service factor in s 9(3) is met for a particular claimant, decision makers must consult the VEA Schedule 2 items listed.

The instrument records its own legislative history in the endnotes. Key dates and amendments are as follows.

Original instrument

• Statement of Principles concerning myeloma (Reasonable Hypothesis) (No. 95 of 2021) was registered on 24 August 2021 and commenced on 20 September 2021 (Endnote 3, legislation history).

2024 amendment

• An Amendment Statement of Principles concerning factors relating to being in Vietnam (Reasonable Hypothesis) (No. 27 of 2024) was registered on 28 February 2024 and commenced on 26 March 2024 (Endnote 3). The compilation reflects that commencement date for the amendment.

Nature of amendment(s)

• The amendment history table in Endnote 4 identifies that Schedule 1 - Dictionary entry for the definition of "being (a) on land in Vietnam; or (b) at sea in Vietnamese waters" was revised by rs. No. 27 of 2024. The endnote records: "Schedule 1 - Dictionary - ' "being (a) on land in Vietnam; or (b) at sea in Vietnamese waters"….' | rs. No. 27 of 2024" (Endnote 4). The compiled Schedule 1 reflects that the meaning of those phrases is tied to Items 3A, 3B, 4 and 8 of Schedule 2 of the VEA.

Other editorial amendments

• Endnote 4 also lists entries "Section 2………………. rep LA s 48D" and "Section 4………………. rep LA s 48C". Those entries indicate that certain provisions originally in the instrument were repealed under provisions of the Legislation Act 2003. The compiled instrument shows sections numbered 1, 3, 5 and so on, consistent with editorial and structural amendments effected during compilation. The endnotes caution that misdescribed amendments may be annotated as "(md not incorp)" where they could not be given effect.

Notes on compilation

• The compilation includes a prefatory notice explaining that uncommenced amendments are not shown, and that modifications effected by another law may operate without textual amendment being displayed in the compilation. For practitioners, this means that the Register may hold additional details about uncommenced amendments or modifications not visible in the compiled text (prefatory notes).

Implications for practice

• The 2024 amendment narrows or clarifies the geographic and itemised basis for the Vietnam service factor by explicit cross‑reference to Schedule 2 Items of the VEA. Claimants and decision makers must therefore consult the VEA Schedule 2 items listed in Schedule 1 to determine whether a claimant’s service falls into the defined Vietnam service categories for the s 9(3) factor.

The compiled instrument and its endnotes do not record any litigation history. The instrument itself contains no reference to judicial decisions, case law or tribunal rulings. The endnotes set out legislative and amendment history only, and there is no entry that identifies judicial consideration or that cites any appeals or litigation concerning the content or application of this Statement of Principles.

What the absence of recorded litigation means in this source

• The source material is a legislative instrument compilation and endnotes. Those materials are not the repository for comprehensive case law reporting. The compilation notes explicitly record amending laws and amendment history (Endnotes 3 and 4) but do not provide judicial histories. Practitioners seeking litigation outcomes that involve application of this SoP must consult tribunal and court databases, administrative law reports, and VEA/MRCA decision registries outside the instrument.

Litigation avenues and likely focal points if disputes arise

• Although the instrument contains no litigation history, disputes about the application of a SoP typically arise when claimants or decision makers differ on whether the factual thresholds or service nexus requirements have been satisfied. Likely litigable issues, based on the text, include:
  • Quantification disputes: whether radiation dose reconstructions or benzene exposure reconstructions meet the thresholds specified in s 9 and Schedule 1.
  • Temporal issues: whether first exposure timing and the 5‑year minimum intervals have been satisfied.
  • Service nexus: whether the identified factor can be related to the person's relevant service in the sense required by s 10(1).
  • Scope and interpretation of definitions: for example, whether a particular water production method on board a vessel qualifies as evaporative distillation of estuarine Vietnamese waters (s 9(3)(c) and Schedule 1 potable water/estuarine definitions).
  • Cross‑SoP application under s 11: whether another SoP covers a referenced injury or disease and how overlapping SoPs should be reconciled.

Procedural context for disputes

• Any litigation or merits review would engage the decision procedures, review bodies and appeal mechanisms established by the VEA and MRCA. The SoP will be central evidence in those proceedings but cannot be the sole source of rights or jurisdictional authority; primary Acts and administrative law processes will frame legal challenges.

This section highlights predictable pitfalls, evidentiary traps and operational risks that follow from the instrument’s text.

Strict quantitative thresholds and timing requirements

• The SoP contains strict numeric and temporal thresholds that can determine success or failure of a claim. Examples include: ionising radiation cumulative equivalent dose of 0.1 sievert to bone marrow (s 9(1)); TCDD‑contaminated agent contact for at least 1,000 hours within a consecutive 10‑year period with first exposure at least 5 years before onset (s 9(2)); benzene exposure either 2,500 cumulative hours within a continuous 5‑year period or greater than 10 ppm‑years (s 9(6)-(7)); and BMI of 25 or greater for at least 5 continuous years (s 9(8)). Failure to demonstrate the precise numerical requirement will mean the reasonable hypothesis is not raised.

First exposure timing requirement

• Several factors require that the first relevant exposure occurred at least 5 years before clinical onset (s 9(1), (2)(b), (3), (6), (7)). Practically, claimants must produce reliable evidence of the date of first exposure and the date of clinical onset. Clinical onset may be ambiguously recorded; the SoP does not define "clinical onset" beyond common medical understanding, so claimants must be meticulous in establishing onset dates.

Definition dependence on external technical materials

• Radiation dose determinations must be computed "in accordance with the methodology set out in" the ARPANSA Guide as in force on 2 August 2017 (Schedule 1). If dose reconstruction uses a different methodology or a later edition, decision makers may reject it as inconsistent with the SoP. Likewise, reliance on ICD‑10‑AM coding without satisfying the textual definition in s 7(2) will be insufficient.

Vietnam service scope requires cross‑checking VEA Schedule 2

• The SoP ties the Vietnam factor to Items 3A, 3B, 4 and 8 of Schedule 2 of the VEA (Schedule 1). Practitioners must consult those items to confirm whether particular locations, dates and circumstances fall within the specified service areas. The 2024 amendment adjusted the dictionary entry to that effect; failure to check the VEA Schedule 2 items risks misidentifying eligible Vietnam service.

Benzene metric complexity

• Schedule 1 sets out multiple ways of meeting benzene exposure criteria: cutaneous contact or ingestion with liquids containing >1% benzene by volume; inhalation where 8‑hour time‑weighted average benzene concentration exceeds 5 ppm; or cumulative measures in hours or ppm‑years (Schedule 1, benzene definitions). Reconstructing historical time‑weighted averages, establishing ppm‑years, and proving cumulative hours will commonly require detailed occupational hygiene evidence. Absence of contemporaneous monitoring data can be decisive.

Practical checklist for claim preparation and adjudicator assessment, mapped to the instrument’s requirements. This is a work plan based on the instrument text; adapt to case specifics.

1. Confirm applicability to the claim

• Verify that the claim falls under the VEA s 120A or MRCA s 338 frameworks referenced in s 5. If not, this SoP does not apply.

2. Establish the diagnosis and timing of clinical onset

• Obtain the treating oncologist’s records and pathology reports to confirm the diagnosis as a form of myeloma included in s 7(2). Record the date identified as the clinical onset of myeloma for all temporal tests in s 9.

3. Determine which s 9 factor(s) to pursue

• Review the claimant’s service and health history against each factor in s 9. A single qualifying factor, properly linked to relevant service, is sufficient to raise the reasonable hypothesis. Prioritise factors that are best supported by accessible documentary evidence.

4. For radiation exposure (s 9(1))

• Commission or obtain a cumulative equivalent dose reconstruction for bone marrow calculated "in accordance with" the ARPANSA Guide noted in Schedule 1, using the edition as in force on 2 August 2017. Ensure the report expresses the dose in sieverts and addresses exclusion of normal Australian background radiation as required by the Schedule 1 definition.

5. For TCDD (s 9(2))

• Document activities matching the Schedule 1 list (decanting, spraying, handling treated timber, use of contaminated cutting oils, etc.). Quantify cumulative hours of contact and demonstrate that the cumulative total is at least 1,000 hours within a consecutive 10‑year period, and that first exposure occurred at least 5 years before clinical onset.

6. For Vietnam service (s 9(3))

• Verify service records, ship logs and muster rolls to show presence on land in Vietnam or at sea in Vietnamese waters. If relying on potable water exposure, obtain ship supply records or testimony about on‑board water production methods and confirm evaporative distillation of estuarine Vietnamese waters. Cross‑check against Items 3A, 3B, 4 and 8 of Schedule 2 of the VEA as required by Schedule 1.